Search

Johnson and Johnson

Lezárt

SzektorEgészségügy

266.14 -1.03

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

266.63

Maximum

270.95

Fő mutatók

By Trading Economics

Bevétel

299M

5.5B

Értékesítés

1.2B

25B

P/E

Szektor átlag

31.966

56.597

Egy részvényre jutó nyereség

2.9

Osztalékhozam

1.88

Profit margin

21.865

Munkavállalók

138,200

EBITDA

721M

9B

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

1.88%

2.18%

Következő eredményjelentés

2026. okt. 13.

Következő osztalékfizetési dátum

2026. dec. 8.

Következő korábbi osztalék dátum

2026. nov. 24.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

45B

663B

Előző nyitás

267.17

Előző zárás

266.14

Hangulat hírek alapján

By Acuity

38%

62%

106 / 339 Rangsor szerint Healthcare

Johnson and Johnson Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 9. 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

2026. szept. 8. 20:02 UTC

Social Media

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

2026. szept. 5. 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

2026. szept. 4. 20:08 UTC

News

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

2026. szept. 3. 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2026. szept. 2. 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

2026. szept. 1. 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

2026. aug. 31. 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

2026. aug. 29. 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

2026. aug. 28. 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

2026. aug. 27. 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

2026. aug. 26. 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

2026. aug. 25. 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

2026. aug. 24. 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

2026. aug. 21. 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

2026. aug. 20. 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

2026. aug. 19. 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

2026. aug. 18. 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

2026. aug. 17. 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

2026. aug. 14. 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

2026. aug. 13. 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

2026. aug. 12. 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

2026. aug. 11. 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

2026. aug. 10. 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

2026. aug. 8. 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

2026. aug. 7. 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

2026. aug. 6. 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

2026. aug. 5. 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

2026. aug. 4. 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

2026. aug. 3. 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

Társak összehasonlítása

Árváltozás

Johnson and Johnson Előrejelzés

Értékelési konszenzus

By TipRanks

Erős vétel

17 ratings

14

Vétel

3

Tartás

0

Eladás

Hangulat

By Acuity

106 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat